Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > The Ventripoint – GE Partnership
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by jopatcloon Mar 25, 2024 1:09pm
52 Views
Post# 35951098

RE:The Ventripoint – GE Partnership

RE:The Ventripoint – GE PartnershipGood Comment
@cardinal this week
 
8
 
@cardinal should see the sales tstart to flow now
 
8
Sales news at any time! 4.0 Exciting moment, Dr.George Adams,Bart Hendriks,Hugt MacNaught,Dr.luc Mertens and team...
"This is the best Board I have ever worked with and you should be assured by its commitment and expertise." - George Adams
"The next version of our technology — VMS+ 4.0 — is on schedule and is expected to be on the market in the second quarter of 2024."

and and just 1 weeks before ACC.24, April 6-8, 2024 in Atlanta, Georgia? A Global Heartbeat: From Europe to North America,Post Bart A Global Heartbeat: From Europe to North America, leading hospitals have embraced Ventripoint's technology. With VMS+3.2, Ventripoint is expanding its reach, aiming to make this superior diagnostic tool a staple in hospitals and clinics worldwide.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities